Loading clinical trials...
Loading clinical trials...
Phase I, First-in-human Trial in Healthy Volunteers to Examine Increasing Single and Repeated Oral Doses of TMC647055, Followed by a Repeated-dose Part in Chronic HCV-genotype 1 Infected Patients to Examine TMC647055 Given Alone or in Combination With TMC435
Conditions
Interventions
TMC647055
Placebo
+8 more
Locations
1
Belgium
Antwerp, Belgium
Start Date
April 1, 2010
Primary Completion Date
November 1, 2011
Completion Date
November 1, 2011
Last Updated
March 4, 2013
NCT06953479
NCT03135886
NCT05968573
NCT05042544
NCT05870969
NCT05361603
Lead Sponsor
Tibotec Pharmaceuticals, Ireland
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions